• Acambis plc, of Cambridge, UK, said it completed delivery of the entire 2.7 million doses of its ACAM2000 smallpox vaccine to the Centers for Disease Control and Prevention ahead of schedule. As a result, the company expects to record total revenues of about £9.5 million (US$18.8 million) in 2007.

• Can-Fite BioPharma Ltd., of Petach Tikva, Israel, signed two worldwide research laboratories to promote its second drug, CF102, and facilitate joint research to investigate the drug's effect on hepatitis C virus replication in hepatocytes, as well as to elucidate the molecular mechanisms underlying the antiviral activity of CF102. One agreement was signed with a researcher from the Rabin Medical Center in Israel, while the second was signed with a researcher from the Center of Neurovirology and Cancer Biology at Philadelphia Temple University. Financial terms were not disclosed.

• OxiGene Inc., of Waltham, Mass., reported positive preclinical results showing that its topical formulation of Zybrestat in ophthalmological indications is absorbed when applied to the surface of the eye and resulted in concentrations of drug target tissues in the back of the eye in rabbit models. Based on those results, the company is proceeding with further preclinical studies in nonrodent models, which, if consistent with data from rabbit and rodent studies, are expected to provide support for an investigational new drug application for the topical formulation in the first half of this year. The company also continues to test an intravenous form of Zybrestat in clinical trials in myopic macular degeneration.

• Neopharm Inc., of Waukegan, Ill., received a non-compliance notice from Nasdaq, stating that the company's common stock has closed below the minimum $1 price for the last 30 consecutive business days. The company will have 180 days, until June 23, to regain compliance.

• Pfizer Inc., of New York, completed the cash tender offer to purchase all outstanding shares of Wellesley, Mass.-based Coley Pharmaceuticals Group Inc., purchasing a total of 24.1 million shares. Pfizer said it intends to complete the estimated $164 million merger, announced in November, within the several days. (See BioWorld Today, Nov. 19, 2007.)

• PSivida Ltd., of Perth, Australia, received a non-compliance letter from Nasdaq, stating that the company's common stock has traded below the $1 minimum bid price for the last 30 consecutive business days. The company has 180 days, or until June 24, to regain compliance.

• Salix Pharmaceuticals Ltd., of Raleigh, N.C., submitted a new drug application to market granulated mesalamine based on results from two six-month studies showing that a greater proportion of ulcerative colitis patients who received doses once-daily with the drug remained relapse-free compared to those on placebo. The company anticipates a 10-month review period.